Early antibody treatment, inflammation, and risk of post-COVID conditions.

Early antibody treatment, inflammation, and risk of post-COVID conditions.

Publication date: Sep 19, 2023

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14. 5%) and anosmia (14. 5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2. 69 [1. 93-3. 81]), older age (AOR = 1. 32 [1. 17-1. 50]), and elevated baseline levels of IL-6 (AOR = 1. 59 [1. 02-2. 47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

Open Access PDF

Concepts Keywords
Diabetes chemokines
Future COVID-19
Pccs COVID-19 serotherapy
Sandwich cytokines
Therapy interleukin-6
post-COVID condition (PCC)


Type Source Name
disease MESH inflammation
disease MESH post-COVID conditions
disease MESH morbidity
drug DRUGBANK Factor IX Complex (Human)
disease MESH obesity
disease MESH diabetes mellitus
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO symptom
disease IDO intervention
disease VO time
disease MESH infection
disease MESH sequelae

Original Article

(Visited 2 times, 1 visits today)